Closing the regulatory regress: GMP accreditation in stem cell laboratories

Neil Stephens*, Jamie Lewis, Paul Atkinson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Contemporary biomedical research is conducted amidst regimes of national and transnational regulation. Regulation, like rules generally, cannot specify all the practicalities of their application. Regulations for biomedical research impose considerable constraints on laboratories and others. In principle, there is a never-ending regress whereby scientists have to provide increasingly more guarantees that protocols have been followed, standards reached and maintained, and rules adhered to. In practice, regulatory regress is not the actual outcome, as actors find ways of establishing closure for all practical purposes. Based on ethnographic case studies of two sites of biomedical work - the UK Stem Cell Bank and an anonymous laboratory working with primary human foetal material - this article documents the possibility of regulatory regress and strategies aimed at its closure.

Original languageEnglish
Pages (from-to)345-360
Number of pages16
JournalSociology of Health and Illness
Volume35
Issue number3
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Good manufacturing practice (GMP)
  • Regress
  • Regulation
  • Stem cells
  • UK Stem Cell Bank

ASJC Scopus subject areas

  • Health(social science)
  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint

Dive into the research topics of 'Closing the regulatory regress: GMP accreditation in stem cell laboratories'. Together they form a unique fingerprint.

Cite this